This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
MANGO OV2 was a phase 4, single-group study evaluating soluble and tissue biomarkers in patients with ovarian cancer receiving carboplatin, paclitaxel, and bevacizumab.
| Feature | MANGO OV2 |
|---|---|
| Condition | Ovarian Cancer |
| Phase | Phase 4 |
| Design | Single-group |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | National Cancer Institute, Naples |
| Interventions | Bevacizumab, paclitaxel, carboplatin |
2. Clinical Question
Population
Patients with ovarian cancer.
Intervention
Carboplatin + paclitaxel with bevacizumab.
Comparator
No comparator arm; the study uses a single-group design.
Primary question
How do soluble and tissue biomarker measurements relate to the clinical course of treated patients?
3. Trial Design
| Design element | Description |
|---|---|
| Allocation | Not applicable |
| Model | Single group |
| Number of arms | 1 |
| Masking | None |
| Enrollment | 400 |
4. Endpoints
| Endpoint | Time frame |
|---|---|
| Expression of soluble and tissutal biomarkers | Measured at baseline, at completion of chemotherapy, at disease progression or bevacizumab completion up to 15 months for each patient |
5. Planned Analysis
The registry identifies the primary endpoint as expression of soluble and tissue biomarkers measured at multiple clinical time points. No formal statistical analyses were posted to ClinicalTrials.gov.
For biomarker studies with repeated measurements, analyses commonly evaluate changes over time, relationships between biomarker measurements and clinical characteristics, and associations between biological measurements and disease outcomes when those outcomes are available.
Repeated biomarker measurements
Measurements collected at baseline and later treatment milestones require statistical methods that account for within-patient correlation.
Approaches such as longitudinal models may be considered when the objective is to describe biomarker trajectories over time.
6. Statistical Methodology
Single-group study interpretation
Because MANGO OV2 uses a single-group design, treatment comparisons between randomized groups are not part of the study structure. Statistical interpretation focuses on describing biomarker patterns and their relationship to clinical information collected during follow-up.
Longitudinal biomarker analysis
Repeated biomarker measurements introduce correlation because multiple observations come from the same patient. Appropriate statistical models account for this dependency rather than treating every measurement as unrelated.
Association versus causation
Associations between biomarkers and clinical characteristics can identify patterns, but they do not by themselves establish that a biomarker causes a clinical outcome.
7. Statistical Methods Explained
Why are repeated measurements important?
Biomarkers measured at baseline and later treatment points provide information about change over time. The statistical challenge is separating true biological change from patient-to-patient variability.
Why is a single-group design different from a randomized trial?
Without a comparator group, the study can characterize biomarker behavior during treatment but cannot estimate a randomized treatment effect.
What does biomarker association mean?
An observed association indicates that two measurements vary together. It does not prove that changing one measurement would change clinical outcomes.
Why does timing matter in biomarker studies?
A measurement collected before treatment answers a different biological question than a measurement collected after chemotherapy completion or disease progression.
8. Limitations
- No randomized comparator: the single-group design limits causal comparisons between treatment strategies.
- Biomarker complexity: biological measurements may vary within patients over time.
- Missing longitudinal measurements: biomarker follow-up may be affected by treatment completion, progression, or availability of samples.
- Registry reporting: the ClinicalTrials.gov record does not report formal statistical analyses or efficacy results.
9. Why This Trial Matters Statistically
| Concept | How it appears in MANGO OV2 |
|---|---|
| Biomarker analysis | Primary endpoint based on soluble and tissue biomarker expression |
| Longitudinal data | Measurements collected at multiple treatment-related time points |
| Single-group design | No randomized comparator arm |
| Clinical interpretation | Biological patterns must be interpreted separately from treatment-effect estimates |
10. Sources
- ClinicalTrials.gov record: NCT01706120